Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?.

Abdominal radiology (New York)

Xie S, Zhang Y, Chen J, Jiang T, Liu W, Rong D, Sun L, Zhang L, He B, Wang J.
PMID: 34773467
Abdom Radiol (NY). 2021 Nov 13; doi: 10.1007/s00261-021-03339-7. Epub 2021 Nov 13.

PURPOSE: To evaluate whether the Liver Imaging Reporting and Data System (LI-RADS) v2018 LR-5 criteria can be modified to increase sensitivity without reducing specificity for diagnosing 10-19 mm hepatocellular carcinoma (HCC) on gadoxetic acid-enhanced magnetic resonance imaging (MRI).METHODS: A...

Cite
Xie S, Zhang Y, Chen J, et al. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?. Abdom Radiol (NY). 2021;doi: 10.1007/s00261-021-03339-7.
Xie, S., Zhang, Y., Chen, J., Jiang, T., Liu, W., Rong, D., Sun, L., Zhang, L., He, B., & Wang, J. (2021). Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?. Abdominal radiology (New York), . https://doi.org/10.1007/s00261-021-03339-7
Xie, Sidong, et al. "Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?." Abdominal radiology (New York) vol. (2021). doi: https://doi.org/10.1007/s00261-021-03339-7
Xie S, Zhang Y, Chen J, Jiang T, Liu W, Rong D, Sun L, Zhang L, He B, Wang J. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?. Abdom Radiol (NY). 2021 Nov 13; doi: 10.1007/s00261-021-03339-7. Epub 2021 Nov 13. PMID: 34773467.
Copy Download .nbib Format: NLM
Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma.

Cancer immunology, immunotherapy : CII

Sun L, Mu L, Zhou J, Tang W, Zhang L, Xie S, Chen J, Wang J.
PMID: 33993366
Cancer Immunol Immunother. 2022 Jan;71(1):25-38. doi: 10.1007/s00262-021-02957-w. Epub 2021 May 16.

BACKGROUND: Tumor-infiltrating CD8 cells and expression of programmed cell death ligand 1 (PD-L1) are immune checkpoint markers in patients with hepatocellular carcinoma (HCC). We aimed to determine the ability of preoperative gadoxetic acid-enhanced magnetic resonance imaging (MRI) findings to...

Cite
Sun L, Mu L, Zhou J, et al. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer Immunol Immunother. 2021;71(1):25-38doi: 10.1007/s00262-021-02957-w.
Sun, L., Mu, L., Zhou, J., Tang, W., Zhang, L., Xie, S., Chen, J., & Wang, J. (2022). Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer immunology, immunotherapy : CII, 71(1), 25-38. https://doi.org/10.1007/s00262-021-02957-w
Sun, Lin, et al. "Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma." Cancer immunology, immunotherapy : CII vol. 71,1 (2022): 25-38. doi: https://doi.org/10.1007/s00262-021-02957-w
Sun L, Mu L, Zhou J, Tang W, Zhang L, Xie S, Chen J, Wang J. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer Immunol Immunother. 2022 Jan;71(1):25-38. doi: 10.1007/s00262-021-02957-w. Epub 2021 May 16. PMID: 33993366.
Copy Download .nbib Format: NLM
Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma.

Cancer immunology, immunotherapy : CII

Sun L, Mu L, Zhou J, Tang W, Zhang L, Xie S, Chen J, Wang J.
PMID: 33993366
Cancer Immunol Immunother. 2021 May 16; doi: 10.1007/s00262-021-02957-w. Epub 2021 May 16.

BACKGROUND: Tumor-infiltrating CD8 cells and expression of programmed cell death ligand 1 (PD-L1) are immune checkpoint markers in patients with hepatocellular carcinoma (HCC). We aimed to determine the ability of preoperative gadoxetic acid-enhanced magnetic resonance imaging (MRI) findings to...

Cite
Sun L, Mu L, Zhou J, et al. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer Immunol Immunother. 2021;doi: 10.1007/s00262-021-02957-w.
Sun, L., Mu, L., Zhou, J., Tang, W., Zhang, L., Xie, S., Chen, J., & Wang, J. (2021). Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer immunology, immunotherapy : CII, . https://doi.org/10.1007/s00262-021-02957-w
Sun, Lin, et al. "Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma." Cancer immunology, immunotherapy : CII vol. (2021). doi: https://doi.org/10.1007/s00262-021-02957-w
Sun L, Mu L, Zhou J, Tang W, Zhang L, Xie S, Chen J, Wang J. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer Immunol Immunother. 2021 May 16; doi: 10.1007/s00262-021-02957-w. Epub 2021 May 16. PMID: 33993366.
Copy Download .nbib Format: NLM
Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma.

Cancer immunology, immunotherapy : CII

Sun L, Mu L, Zhou J, Tang W, Zhang L, Xie S, Chen J, Wang J.
PMID: 33993366
Cancer Immunol Immunother. 2022 Jan;71(1):25-38. doi: 10.1007/s00262-021-02957-w. Epub 2021 May 16.

BACKGROUND: Tumor-infiltrating CD8 cells and expression of programmed cell death ligand 1 (PD-L1) are immune checkpoint markers in patients with hepatocellular carcinoma (HCC). We aimed to determine the ability of preoperative gadoxetic acid-enhanced magnetic resonance imaging (MRI) findings to...

Cite
Sun L, Mu L, Zhou J, et al. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer Immunol Immunother. 2021;71(1):25-38doi: 10.1007/s00262-021-02957-w.
Sun, L., Mu, L., Zhou, J., Tang, W., Zhang, L., Xie, S., Chen, J., & Wang, J. (2022). Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer immunology, immunotherapy : CII, 71(1), 25-38. https://doi.org/10.1007/s00262-021-02957-w
Sun, Lin, et al. "Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma." Cancer immunology, immunotherapy : CII vol. 71,1 (2022): 25-38. doi: https://doi.org/10.1007/s00262-021-02957-w
Sun L, Mu L, Zhou J, Tang W, Zhang L, Xie S, Chen J, Wang J. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer Immunol Immunother. 2022 Jan;71(1):25-38. doi: 10.1007/s00262-021-02957-w. Epub 2021 May 16. PMID: 33993366.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries